Around £45 billion in NHS funding will be diverted from other NHS care by 2036 to pay more for new medicines under the UK-U.S. trade deal agreed last December unless more funding is made available to cover the additional costs, suggests an analysis published by The BMJ .
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗